High-yield points
- Pediatric pineal masses: germinoma about 1/3, NGGCT about 1/4, pineoblastoma about 1/5, then glioma and ATRT .
- Workup before any surgery:
- serum and CSF AFP and β-hCG;
- MRI of the whole neuraxis;
- CSF cytology .
- NGGCT by markers (SIOP): AFP >25 ng/mL and/or β-hCG >50 IU/L in serum or CSF means treat without biopsy .
- AFP over 1,000 ng/mL predicts relapse .
- CSF PLAP strongly supports germinoma where it is available .
- Marker-negative with hydrocephalus: ETV plus endoscopic biopsy.
- Yield: 85–91%.
- Caution: diagnosis is revised in about 20% .
- Germinoma:
- Surgery: biopsy only.
- Treatment: chemotherapy then whole-ventricular RT plus boost, or reduced-dose CSI.
- Outcome: EFS over 90% .
- NGGCT:
- Treatment: chemotherapy, then second-look resection of any residual, then RT.
- Outcome: 5-year EFS about 72–84% .
- Avoid CSI? Reduced RT without CSI risked spinal relapse .
- Growing teratoma: resect it .
- Pineoblastoma:
- Groups: PB-miRNA1/2 (favorable; reduced-dose CSI is adequate) vs. MYC/FOXR2 and RB1 (infants, dismal) .
- PPTID: KBTBD4 .
- Pineal cysts: 92% stable. Follow-up is optional in older children .
- Approaches:
- SCIT: midline, below the veins.
- Occipital transtentorial: large, lateral or downward extension.
- Posterior interhemispheric transcallosal: upward or third-ventricular extension.
- Transparietal transventricular: atrial extension.
- Endoscopic: biopsy plus ETV .
Landmark papers
- SIOP CNS GCT 96 (Calaminus et al., Neuro Oncol 2013): in localized germinoma, reduced-dose CSI alone and chemotherapy followed by focal radiation gave the same EFS and OS, but 6 of 7 relapses in the combined arm were in the ventricles outside the focal field .
- COG ACNS1123 (Bartels et al., Neuro Oncol 2022): localized germinoma treated with carboplatin/etoposide, then response-based RT. 3-year PFS was 94.5% (18 Gy) and 93.8% (24 Gy) .
Pineal region tumors make up 2.7–11% of pediatric CNS tumors .
- Their location defines the presentation:
- obstructive hydrocephalus from aqueductal compression;
- Parinaud syndrome from tectal compression.
- Their biology defines the treatment.
- Most pediatric masses here are germ cell tumors. Many need no open surgery at all, because serum and CSF tumor markers, or a small endoscopic biopsy, make the diagnosis .
Differential diagnosis
- Pediatric series (151 children, 30 years) :
- Distribution:
- germinoma 33.1%;
- NGGCT 27.2%;
- pineoblastoma 22.5%;
- glioma 12.6%;
- embryonal (ATRT) 3.3%.
- 5-year OS:
- germinoma 88%;
- NGGCT 67.2%;
- glioma 72.6%;
- pineoblastoma 40.7%;
- ATRT 0%.
- Another 80-child surgical series (occipital transtentorial) :
- Mix:
- 32 germ cell tumors, of which 18 were teratomas;
- 22 benign astrocytomas;
- 13 pineal parenchymal tumors;
- 5 ATRTs;
- 3 papillary tumors.
- The working differential:
- Germ cell tumors:
- germinoma;
- NGGCTs: yolk sac tumor, embryonal carcinoma, choriocarcinoma, immature or mature teratoma, and mixed tumors.
- Pineal parenchymal tumors:
- pineocytoma;
- pineal parenchymal tumor of intermediate differentiation (PPTID);
- pineoblastoma .
- Other WHO 2021 pineal tumors:
- papillary tumor of the pineal region;
- desmoplastic myxoid tumor of the pineal region, SMARCB1-mutant .
- Gliomas: tectal and exophytic midbrain gliomas (often pilocytic), and thalamic gliomas .
- Embryonal: ATRT .
- Benign:
- pineal cyst;
- meningioma of the velum interpositum/tentorium;
- vein of Galen malformation (a vascular mimic).
Germ cell tumors: diagnosis by tumor markers
- Always measure AFP and β-hCG in both serum and CSF before any surgery .
- Why both compartments: a marker may be elevated in only one.
- CSF sampling: lumbar CSF if safe. Ventricular CSF is taken when ICP is high (e.g., at EVD or ETV) .
- SIOP CNS GCT 96 definitions :
- Secreting (malignant) NGGCT:
- Thresholds: AFP >25 ng/mL and/or β-hCG >50 IU/L in serum or CSF.
- No biopsy needed. These are pragmatic thresholds meant to avoid the morbidity of upfront surgery. Some hCG-secreting germinomas and AFP-secreting teratomas may fall inside them .
- Germinoma:
- Marker limits: AFP 25 ng/mL or less and β-hCG 50 IU/L or less.
- Histology: required .
- Mildly elevated hCG, from syncytiotrophoblastic giant cells, is compatible with germinoma.
- What the markers mean:
- Elevated AFP → yolk sac component (also immature teratoma and embryonal carcinoma, variably).
- Markedly elevated β-hCG → choriocarcinoma.
- Marker-negative → germinoma, mature teratoma, or a non-germ-cell tumor. Biopsy is required.
- Prognostic markers in NGGCT:
- AFP over 1,000 ng/mL at diagnosis (serum or CSF) predicted relapse: 58% vs. 22% in SIOP CNS GCT 96 .
- Increased serum AFP was also adverse in COG ACNS0122 .
- β-hCG carried no added prognostic weight .
- CSF placental alkaline phosphatase (PLAP), a germinoma marker:
- Diagnostic value: in all germinomas, CSF PLAP was elevated, and its absence excluded germinoma (74 patients) .
- At an 8 pg/mL cutoff: sensitivity 100% and specificity 95.2% (134 patients) .
- Availability: used routinely in Japan, but not widely available in North America.
- Staging:
- MRI of the whole neuraxis plus CSF cytology.
- Bifocal disease (pineal plus suprasellar) is treated as non-metastatic germinoma .
Biopsy and hydrocephalus
- Marker-negative tumor with hydrocephalus: do an endoscopic third ventriculostomy (ETV) with endoscopic biopsy in one sitting.
- This is the method of choice .
- Diagnostic yield:
- 91.4% across 70 biopsies ;
- 85% in 46 endoscopic biopsies .
- Sampling error is real:
- In one series the diagnosis was amended in 21% after a later procedure, because mixed germ cell and pineal tumors are heterogeneous .
- Frozen and final pathology disagreed in 18.4% in another .
- Trend toward less surgery:
- ETV has replaced shunting.
- Most children who had an ETV also had endoscopic biopsy (73%).
- Open resection carried more complications without lower recurrence or mortality .
- Hydrocephalus is near-universal: 74 of 80 children. It was managed before craniotomy by:
- ETV, 33;
- EVD, 26;
- shunt, 15 .
Germinoma: treatment
- Surgery: biopsy only. Germinomas are highly sensitive to chemotherapy and radiation, so there is no role for resection .
- SIOP CNS GCT 96 (localized germinoma) :
- Compared: reduced-dose CSI alone vs. chemotherapy followed by focal radiation.
- Survival: same EFS and OS.
- PFS: better with CSI (0.97 vs. 0.88).
- Where the combined arm relapsed: most relapses (6 of 7) were in the ventricles outside the focal field. Hence whole-ventricular irradiation (WVI) became standard.
- Metastatic germinoma: CSI cured nearly all (EFS/OS 0.98).
- COG ACNS1123 (localized germinoma, carboplatin/etoposide, then response-based RT) :
- Complete responders: 18 Gy WVI + 12 Gy boost.
- Partial responders: 24 Gy WVI + 12 Gy.
- 3-year PFS: 94.5% (18 Gy) and 93.8% (24 Gy).
- Formally failed noninferiority by design, but cognition was largely preserved.
- Consensus: over 90% 5-year EFS with chemotherapy followed by WVI plus boost, without aggressive surgery .
NGGCT: treatment
- Backbone: neoadjuvant chemotherapy → second-look surgery for residual disease → radiotherapy .
- COG ACNS0122 (102 patients) :
- Treatment:
- 6 cycles of carboplatin/etoposide alternating with ifosfamide/etoposide;
- second-look surgery for less than complete response;
- then CSI.
- Response to chemotherapy: CR or PR in 69%.
- Outcome at 5 years: EFS 84% and OS 93%.
- COG ACNS1123, reduced RT (107 patients) :
- Who: responders (CR or PR, with or without second-look surgery).
- Radiation: 30.6 Gy WVI + 54 Gy tumor bed instead of CSI.
- 3-year PFS: 87.8%.
- But relapses were spinal: all failures included the spine.
- SIOP CNS GCT 96 (localized NGGCT: chemotherapy then focal 54 Gy) :
- Localized disease: 5-year PFS 72% and OS 82%.
- Metastatic disease: 68% and 75% with CSI.
- Adverse factors:
- AFP over 1,000 ng/mL;
- residual disease after treatment, including after second-look surgery.
- Second-look surgery and growing teratoma syndrome:
- Residual disease after chemotherapy should be resected. It is often mature teratoma, or fibrosis/necrosis .
- Growing teratoma syndrome: a mass that enlarges during chemotherapy while markers fall.
- Intracranial tumors develop it sooner, typically at the original site.
- Treat it with complete resection, not more chemotherapy.
- Incomplete resection predicted further events (5-year EFS 41.7% vs. 78.8%) .
Pineal parenchymal tumors
- Pineoblastoma (WHO grade 4; an embryonal-type tumor of the pineal):
- Four consensus molecular groups (221 molecularly characterized PB/PPTID) :
- PB-miRNA1:
- driver: DICER1, DROSHA or DGCR8 alterations;
- outcome: intermediate.
- PB-miRNA2:
- driver: same pathway;
- outcome: favorable.
- PB-MYC/FOXR2:
- who: infants;
- outcome: dismal.
- PB-RB1:
- who: infants; resembles retinoblastoma ("trilateral");
- outcome: dismal.
- Radiation: reduced-dose CSI was adequate for average-risk PB-miRNA1/2 .
- St. Jude trials :
- Average-risk patients aged 3 and older on reduced-dose CSI (23.4 Gy plus boost and chemotherapy): 5-year PFS 100%. High-risk: 56.5%.
- Under 3 (radiation-sparing): 2-year PFS 14% or less.
- Pediatric series: 5-year OS 40.7% overall, and better after GTR .
- PPTID:
- Molecular hallmark: KBTBD4 small in-frame insertions, and no DICER1/DROSHA alterations. This separates it from pineoblastoma .
- Outcome: favorable as a molecular group .
- Pineocytoma:
- Behavior: a slow-growing adult-type tumor; GTR is usually curative.
- Pediatric relevance: uncommon in children.
Pineal cysts
See Pineal Cysts in Children for more detail.
- Common, and usually incidental. In 106 patients under 25 followed for a mean of 3 years :
- Stable: 98 (92%).
- Grew: 6.
- Changed appearance: 2.
- Predictor of change: younger age (mean 5.5 vs. 12.2 years). Size and appearance did not predict change.
- Follow-up imaging is optional in older children .
- Surgery is reserved for:
- hydrocephalus or Parinaud syndrome;
- an atypical, growing cyst.
Surgical approaches
- Who needs open surgery:
- marker-negative tumors that need more than a biopsy (gliomas, pineal parenchymal tumors, papillary tumors, teratomas, ATRT);
- residual NGGCT after chemotherapy;
- growing teratoma.
- Germinomas need only biopsy .
- The anatomic problem: the tumor sits beneath the splenium, above and in front of the culmen, and wrapped by the galenic venous system:
- internal cerebral veins;
- basal veins of Rosenthal;
- precentral cerebellar vein;
- vein of Galen;
- straight sinus.
- Choose the corridor by where the tumor extends relative to these veins and the tentorium.
- Supracerebellar infratentorial (SCIT; Krause, Stein):
- Approach: a midline or paramedian suboccipital craniotomy, then a corridor over the culmen and beneath the tentorium. Gravity retracts the cerebellum when the patient is sitting, semi-sitting or prone with the neck flexed.
- Advantages:
- reaches the tumor below the deep veins;
- needs no cortical incision.
- Best for: midline tumors centered at or below the vein of Galen, extending into the posterior third ventricle.
- Use: the most-used approach in a 151-child series (53.6%), preferred for midline tumors extending into the third ventricle .
- Limitations:
- a steep tentorium;
- lateral extension or supratentorial extension above the veins.
- Sitting position risks: venous air embolism and tension pneumocephalus. These are standard considerations, with precordial Doppler/TEE monitoring.
- Occipital transtentorial (OTA; Poppen):
- Approach:
- positioning: prone, lateral or three-quarter prone;
- exposure: a parieto-occipital craniotomy with gravity retraction of the occipital lobe along the falx;
- tentorium: divided parallel and lateral to the straight sinus.
- What it gives:
- a wide view above and below the tentorium;
- good for large tumors, superior or lateral extension, a steep tentorium, and tumors extending down toward the cerebellum/fourth ventricle. Cavalheiro preferred it for extension toward the fourth ventricle .
- 80-child series :
- GTR: 55 of 80 (69%).
- Mortality: 1 postoperative death.
- Deficits:
- transient: hemiparesis, ataxia;
- permanent: one hemisensory loss, one bilateral oculomotor palsy;
- transient hemianopia: 2;
- Parinaud sign: in 24, of which 16 resolved.
- Most deficits came from midbrain manipulation, not the approach.
- Risk: hemianopia from occipital lobe retraction.
- Posterior interhemispheric transcallosal:
- Approach: parieto-occipital, between the hemispheres and through the posterior corpus callosum/splenium, reaching the tumor from above the deep veins.
- Best for: tumors extending up into the third ventricle or lateral ventricles.
- Use: the most common open approach (59.3%) at one center .
- Risks:
- bridging veins;
- splenial section (disconnection; alexia without agraphia if the dominant visual cortex is also affected);
- working among the internal cerebral veins.
- Transcortical transventricular (transparietal, via the trigone/atrium):
- For: tumors with major lateral extension into the atrium of a lateral ventricle, especially when the ventricle is dilated.
- Cost: a cortical incision, with seizure and visual-field risk.
- Endoscopic:
- Coronal ETV plus biopsy: a frontal (often slightly anterior) burr hole through the foramen of Monro to the posterior third ventricle. This is the first-line procedure for marker-negative tumors .
- Selected small or cystic lesions can be resected endoscopically, including by the supracerebellar route.
- Stereotactic biopsy: an alternative when there is no hydrocephalus. The deep veins raise the bleeding risk.
- Outcome of resection:
- 5-year OS: GTR 69.7% vs. subtotal 40.8% in one series, with the effect varying by histology .
- GTR rates: highest in germ cell tumors (76.6%), lowest in gliomas (30.8%) .
Related topics
- Endoscopic Third Ventriculostomy: ETV with biopsy for hydrocephalus.
- ATRT: a rare pineal-region embryonal tumor.
- Embryonal Brain Tumors: pineoblastoma and its former CNS-PNET group.
- Vein of Galen Malformation: a vascular mimic in the same region.
- Sellar and Suprasellar Lesions: bifocal germinoma and pituitary stalk thickening.
- Low-Grade Gliomas of the Brainstem in Children: tectal gliomas.
- Pineal Cysts in Children: incidental and symptomatic pineal cysts.
- Surgical Approaches to the Pineal Region: step-by-step procedure.
References
- Cavalheiro S, Valsechi LC, Dastoli PA, et al. Outcomes and surgical approaches for pineal region tumors in children: 30 years' experience. J Neurosurg Pediatr 2023;32(2):184–193. doi:10.3171/2023.3.PEDS22468. PMID 37148224. verified
- Murray MJ, Bartels U, Nishikawa R, et al. Consensus on the management of intracranial germ-cell tumours. Lancet Oncol 2015;16(9):e470–e477. doi:10.1016/S1470-2045(15)00244-200244-2). PMID 26370356. verified
- Frappaz D, Dhall G, Murray MJ, et al. EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults. Neuro Oncol 2022;24(4):516–527. doi:10.1093/neuonc/noab252. PMID 34724065. verified
- Tomita T, Alden TD, Dipatri AJ. Pediatric pineal region tumors: institutional experience of surgical managements with posterior interhemispheric transtentorial approach. Childs Nerv Syst 2023;39(9):2293–2305. doi:10.1007/s00381-022-05595-4. PMID 35821434. verified
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
- Calaminus G, Kortmann R, Worch J, et al. SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro Oncol 2013;15(6):788–796. doi:10.1093/neuonc/not019. PMID 23460321. verified
- Calaminus G, Frappaz D, Kortmann RD, et al. Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial. Neuro Oncol 2017;19(12):1661–1672. doi:10.1093/neuonc/nox122. PMID 29048505. verified
- Goldman S, Bouffet E, Fisher PG, et al. Phase II trial assessing the ability of neoadjuvant chemotherapy with or without second-look surgery to eliminate measurable disease for nongerminomatous germ cell tumors: a Children's Oncology Group study. J Clin Oncol 2015;33(22):2464–2471. doi:10.1200/JCO.2014.59.5132. PMID 26101244. verified
- Aihara Y, Watanabe S, Amano K, et al. Placental alkaline phosphatase levels in cerebrospinal fluid can have a decisive role in the differential diagnosis of intracranial germ cell tumors. J Neurosurg 2019;131(3):687–694. doi:10.3171/2018.3.JNS172520. PMID 30265190. verified
- Chiba K, Aihara Y, Oda Y, et al. Sensitivity and specificity of cerebrospinal fluid placental alkaline phosphatase in germinoma: an 8 pg/mL threshold. Neurooncol Adv 2026;8(1):vdag145. doi:10.1093/noajnl/vdag145. PMID 42305115. verified
- Ahmed AI, Zaben MJ, Mathad NV, Sparrow OC. Endoscopic biopsy and third ventriculostomy for the management of pineal region tumors. World Neurosurg 2015;83(4):543–547. doi:10.1016/j.wneu.2014.11.013. PMID 25486584. verified
- Patel N, Marino A, Tang T, et al. Evolution of surgical management of pineal region tumors in the pediatric population: a 17-year experience at a single institution. Pediatr Neurosurg 2024;59(2–3):66–77. doi:10.1159/000538745. PMID 38679003. verified
- Bartels U, Onar-Thomas A, Patel SK, et al. Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study. Neuro Oncol 2022;24(6):974–983. doi:10.1093/neuonc/noab270. PMID 34850169. verified
- Fangusaro J, Wu S, MacDonald S, et al. Phase II trial of response-based radiation therapy for patients with localized CNS nongerminomatous germ cell tumors: a Children's Oncology Group study. J Clin Oncol 2019;37(34):3283–3290. doi:10.1200/JCO.19.00701. PMID 31545689. verified
- Hsieh MY, Chen HH, Lee CY, et al. A case series and literature review on 98 pediatric patients of germ cell tumor developing growing teratoma syndrome. Cancer Med 2023;12(12):13256–13269. doi:10.1002/cam4.6017. PMID 37140211. verified
- Liu APY, Li BK, Pfaff E, et al. Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. Acta Neuropathol 2021;141(5):771–785. doi:10.1007/s00401-021-02284-5. PMID 33619588. verified
- Liu APY, Gudenas B, Lin T, et al. Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathol 2020;139(2):259–271. doi:10.1007/s00401-019-02106-9. PMID 31802236. verified
- Lee JC, Mazor T, Lao R, et al. Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma. Acta Neuropathol 2019;137(5):851–854. doi:10.1007/s00401-019-01990-5. PMID 30877433. verified
- Al-Holou WN, Maher CO, Muraszko KM, Garton HJ. The natural history of pineal cysts in children and young adults. J Neurosurg Pediatr 2010;5(2):162–166. doi:10.3171/2009.9.PEDS09297. PMID 20121364. verified
Verification (2026-11-16):
- Each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed.
- Numbers were checked against the PubMed abstracts.
- The SIOP marker definitions and the AFP >1,000 relapse figures (58% vs. 22%) come from the PMC full texts of references 6 and 7.
- The WHO 2021 pineal tumor list comes from the full text of reference 5.
- Reference 2 (Delphi consensus) is cited for the principle of marker-first workup; its specific thresholds were not checked, since the full text was not accessible.
- Reference 18 has no PubMed abstract; the KBTBD4 statement rests on its title and on reference 16.
Caveats:
- The following are standard teaching, not drawn from the cited abstracts:
- the marker-to-histology correspondence (AFP → yolk sac, hCG → choriocarcinoma);
- pineocytoma behavior;
- the indications for cyst surgery;
- the anatomic descriptions, positioning and risks of each approach (air embolism, hemianopia, splenial disconnection, bridging veins);
- the stereotactic-biopsy caveat.
- All surgical series are retrospective and single-center.
- The figure is an original schematic.